These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 9715819

  • 1. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.
    Feuerstein G, Yue TL, Ma X, Ruffolo RR.
    Prog Cardiovasc Dis; 1998; 41(1 Suppl 1):17-24. PubMed ID: 9715819
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR, Feuerstein GZ.
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [Abstract] [Full Text] [Related]

  • 3. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
    Ruffolo RR, Feuerstein GZ.
    J Cardiovasc Pharmacol; 1998 May; 32 Suppl 1():S22-30. PubMed ID: 9731692
    [Abstract] [Full Text] [Related]

  • 4. Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
    Ruffolo RR, Feuerstein GZ, Ohlstein EH.
    Am J Hypertens; 1998 Jan; 11(1 Pt 2):9S-14S. PubMed ID: 9503101
    [Abstract] [Full Text] [Related]

  • 5. Protective effects of carvedilol in the myocardium.
    Feuerstein GZ, Bril A, Ruffolo RR.
    Am J Cardiol; 1997 Dec 04; 80(11A):41L-45L. PubMed ID: 9412541
    [Abstract] [Full Text] [Related]

  • 6. Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.
    Okafor CC, Perreault-Micale C, Hajjar RJ, Lebeche D, Skiroman K, Jabbour G, Doye AA, Lee MX, Laste N, Gwathmey JK.
    BMC Physiol; 2003 Jul 21; 3():6. PubMed ID: 12873352
    [Abstract] [Full Text] [Related]

  • 7. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
    Feuerstein GZ, Ruffolo RR.
    Eur Heart J; 1996 Apr 21; 17 Suppl B():24-9. PubMed ID: 8733068
    [Abstract] [Full Text] [Related]

  • 8. Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.
    Ruffolo RR, Feuerstein GZ.
    Eur Heart J; 1998 Feb 21; 19 Suppl B():B19-24. PubMed ID: 9519348
    [Abstract] [Full Text] [Related]

  • 9. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
    Feuerstein G, Ruffolo RR.
    Adv Pharmacol; 1998 Feb 21; 42():611-5. PubMed ID: 9327976
    [No Abstract] [Full Text] [Related]

  • 10. Carvedilol in the treatment of chronic heart failure.
    Moe G.
    Expert Opin Pharmacother; 2001 May 21; 2(5):831-43. PubMed ID: 11336626
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
    Cheng J, Kamiya K, Kodama I.
    Cardiovasc Drug Rev; 2001 May 21; 19(2):152-71. PubMed ID: 11484068
    [Abstract] [Full Text] [Related]

  • 13. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.
    Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, Gu JL, Kumar S, Poste G, Ruffolo RR, Feuerstein GZ.
    Circ Res; 1998 Feb 09; 82(2):166-74. PubMed ID: 9468187
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
    Metra M, Covolo L, Pezzali N, Zacà V, Bugatti S, Lombardi C, Bettari L, Romeo A, Gelatti U, Giubbini R, Donato F, Dei Cas L.
    Cardiovasc Drugs Ther; 2010 Feb 09; 24(1):49-60. PubMed ID: 20352314
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
    Bauman JL, Talbert RL.
    J Cardiovasc Pharmacol Ther; 2004 Jun 09; 9(2):117-28. PubMed ID: 15309248
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH.
    N Engl J Med; 1996 May 23; 334(21):1349-55. PubMed ID: 8614419
    [Abstract] [Full Text] [Related]

  • 19. A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts.
    Kramer JH, Weglicki WB.
    Free Radic Biol Med; 1996 May 23; 21(6):813-25. PubMed ID: 8902527
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.